USPTO Examiner GAMETT DANIEL C - Art Unit 1647

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19066279EXOSOME SYSTEMS, PRODUCTS AND METHODSFebruary 2025April 2025Allow100NoNo
18412403EXOSOMES FOR TARGET SPECIFIC DELIVERY AND METHODS FOR PREPARING AND DELIVERING THE SAMEJanuary 2024August 2024Allow710YesNo
18264181MODULATION OF MAMMALIAN CELL LINEAGE BY SYNTHETIC IMMODULINSAugust 2023May 2025Allow2110YesNo
18353182COMPOSITION FOR CULTURING NK CELLS AND METHOD FOR CULTURING NK CELLS USING SAMEJuly 2023January 2024Allow610NoNo
18221658METHODS AND MATERIALS FOR EXPANDING ANTIGEN-SPECIFIC T CELLS IN CULTUREJuly 2023May 2025Abandon2210NoNo
18331353ENHANCED MSC PREPARATIONSJune 2023May 2025Allow2310YesNo
18196779HIGHLY ACTIVE NK CELL AND USE THEREOFMay 2023February 2025Allow2110NoNo
18132713CELL THERAPY COMPOSITIONS AND METHODS OF USE THEREOFApril 2023April 2025Allow2410NoNo
18297491TGFBETA SIGNAL CONVERTORApril 2023March 2025Allow2310NoNo
18296065REGULATORY MACROPHAGES FOR TREATING ANGIOPATHIESApril 2023March 2025Allow2310YesNo
18189826CANCER-KILLING CELLSMarch 2023March 2025Allow2420NoNo
18118941METHODS AND COMPOSITIONS FOR NATURAL KILLER CELLSMarch 2023December 2024Allow2110NoNo
18153900EXPANSION OF GAMMA DELTA T CELLS, COMPOSITIONS, AND METHODS OF USE THEREOFJanuary 2023July 2025Allow3020NoNo
18050915HUMANIZED MONOCLONAL ADVANCED GLYCATION END-PRODUCT ANTIBODYOctober 2022May 2024Allow1920YesNo
17975187CHIMERIC ANTIGEN RECEPTOR DENDRITIC CELL (CAR-DC) FOR TREATMENT OF CANCEROctober 2022August 2023Allow1000NoNo
18050005PREPARATION OF THERAPEUTIC EXOSOMES USING MEMBRANE PROTEINSOctober 2022November 2024Allow2510NoNo
18049999EXOSOMES FOR IMMUNO-ONCOLOGY AND ANTI-INFLAMMATORY THERAPYOctober 2022December 2024Allow2510NoNo
18045868INHIBITION OF CYTOKINE-INDUCED SH2 PROTEIN IN NK CELLSOctober 2022February 2025Abandon2810NoNo
17938549DICKKOPF2 (DKK2) INHIBITION SUPPRESSES TUMOR FORMATIONOctober 2022February 2025Abandon2810NoNo
17900994COMPOSITION OF EXTRACELLULAR VESICLES (EVS) AND MEDICAL USES THEREOFSeptember 2022September 2024Allow2510NoNo
17898540COMPOSITIONS AND METHODS FOR DIFFERENTIATING STEM CELLS INTO NK CELLSAugust 2022October 2024Allow2610NoNo
17867321ENGRAFTMENT OF STEM CELLS WITH A COMBINATION OF AN AGENT THAT TARGETS STEM CELLS AND MODULATION OF IMMUNOREGULATORY SIGNALINGJuly 2022November 2024Allow2710NoNo
17854239Immunoconjugates Targeting HER2June 2022January 2025Abandon3010NoNo
17836998Remnant Tumor Infiltrating Lymphocytes and Methods of Preparing and Using the SameJune 2022October 2024Allow2810NoNo
17825652RENAL CELL POPULATIONS AND USES THEREOFMay 2022February 2025Allow3211NoNo
17752481TUMOR-INFILTRATING LYMPHOCYTES FOR ADOPTIVE CELL THERAPYMay 2022November 2024Allow3010NoNo
17660382Antigen Binding Molecules That Bind LIGHTApril 2022October 2024Allow3010NoNo
17719825Inhibition of Cytokine-Induced SH2 Protein in NK CellsApril 2022September 2022Allow510NoNo
17768061NEW REGULATORY MACROPHAGES AND USES THEREOFApril 2022April 2025Allow3610NoNo
17715558CHIMERIC ANTIGEN RECEPTOR DENDRITIC CELL (CAR-DC) FOR TREATMENT OF CANCERApril 2022September 2022Allow510YesNo
17713766COMPOSITIONS AND METHODS FOR PROMOTING PATENCY OF VASCULAR GRAFTSApril 2022September 2024Allow2910YesNo
17702734HETERODIMERIC PROTEINSMarch 2022June 2025Abandon3920NoNo
17696779METHODS OF CELL THERAPIESMarch 2022June 2023Allow1520NoNo
17654778METHODS AND COMPOSITIONS FOR MODULATING ANGIOGENESIS AND VASCULOGENESISMarch 2022August 2024Allow2910NoNo
17688435METHODS OF PRODUCING MODIFIED NATURAL KILLER CELLS AND METHODS OF USEMarch 2022June 2025Allow4010NoNo
17651673UTILIZING THE INNATE IMMUNE SYSTEM TO DELIVER THERAPEUTIC AGENTSFebruary 2022September 2024Allow3110NoNo
17667934METHODS, COMPOSITIONS, AND KITS FOR PRODUCING BEIGE ADIPOCYTES AND TREATING METABOLIC DISORDERSFebruary 2022January 2025Allow3620NoNo
17544636VACCINES FOR USE IN TREATING VARIOUS DISEASES AND DISORDERSDecember 2021October 2024Abandon3410NoNo
17538719COMPOSITIONS AND METHODS FOR DIFFERENTIATING STEM CELLS INTO NK CELLSNovember 2021May 2022Allow610YesNo
17511322ACTIVATED STEM CELLS AND SYSTEMIC TREATMENT METHODS FOR INFECTED WOUNDSOctober 2021January 2025Allow3920NoNo
17500832NERVE REGENERATIONOctober 2021September 2024Abandon3601NoNo
17499043C1q AND HMGB1 FUSION PROTEINS AND USES THEREOFOctober 2021March 2024Allow2900NoNo
17483193NATURAL KILLER CELL CONTAINING EXOGENOUS MITOCHONDRIUM AND PHARMACEUTICAL COMPOSITION COMPRISING SAMESeptember 2021July 2024Allow3410NoNo
17465284Immunoconjugates Targeting HER2September 2021April 2022Allow710NoNo
17460867Autoimmune Disease Treatment With Chemokine-Loaded Alginate MicroparticlesAugust 2021August 2024Allow3610NoNo
17406504ANTI-DLL3 ANTIBODYAugust 2021August 2024Abandon3610NoNo
17395103DEPLETING TUMOR-SPECIFIC TREGSAugust 2021October 2024Allow3820NoNo
17393466INHIBITION OF CYTOKINE-INDUCED SH2 PROTEIN IN NK CELLSAugust 2021February 2022Allow610NoNo
17384207IL2 AND TNF MUTANT IMMUNOCONJUGATESJuly 2021August 2024Abandon3610NoNo
17380404SITE DIRECTED MUTAGENESIS OF TREM-1 ANTIBODIES FOR DECREASING VISCOSITYJuly 2021June 2024Allow3510NoNo
17379128INHIBITION OF CYTOKINE-INDUCED SH2 PROTEIN IN NK CELLSJuly 2021January 2022Allow610NoNo
17351452WNT/SFRP COMPLEXES, WNT-CONTAINING COMPOSITIONS, WNT-EXPRESSING CELLS, AND METHODS OF MAKING, PURIFYING, AND USING SAMEJune 2021July 2024Abandon3710NoNo
17314438COMPOSITIONS AND METHODS FOR MODULATING AN IMMUNE RESPONSEMay 2021July 2024Abandon3810NoNo
17291808USE OF LACTOFERRIN FOR GENERATING MYELOID-DERIVED SUPPRESSOR CELLSMay 2021January 2025Allow4420NoNo
17307754METHODS FOR THE PRODUCTION OF TCR GAMMA DELTA + T CELLSMay 2021August 2024Allow3920YesNo
17307658METHODS FOR THE PRODUCTION OF TCR GAMMA DELTA + T CELLSMay 2021August 2024Allow3920YesNo
17224966NK CELLS EXHIBITING AN ADAPTIVE PHENOTYPE AND METHODS FOR PREPARING AND FOR USINGApril 2021March 2024Allow3610NoNo
17224047METHODS FOR THE PRODUCTION OF THERAPEUTIC, DIAGNOSTIC, OR RESEARCH ANTIBODIESApril 2021March 2024Allow3610NoNo
17222761MONOCLONAL ANTIBODY COMPOSITION FOR TREATMENT OF PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIAApril 2021April 2025Allow4820NoNo
17211631MONOCLONAL ANTIBODIES AGAINST TISSUE FACTOR PATHWAY INHIBITOR (TFPI)March 2021January 2024Abandon3410NoNo
17211625Cell Expression SystemMarch 2021February 2024Abandon3410NoNo
17209554METHODS AND COMPOSITIONS FOR TREATING DISEASE-RELATED CACHEXIAMarch 2021December 2023Abandon3310NoNo
17195518IL-18 BINDING PROTEIN (IL-18BP) AND ANTIBODIES IN INFLAMMATORY DISEASESMarch 2021October 2023Allow3210NoNo
17274021CHIMERIC RECEPTOR POLYPEPTIDES IN COMBINATION WITH TRANS METABOLISM MOLECULES MODULATING INTRACELLULAR LACTATE CONCENTRATIONS AND THERAPEUTIC USES THEREOFMarch 2021September 2024Abandon4201NoNo
17185801PROCESSES FOR MAKING AND USING A MESENCHYMAL STEM CELL DERIVED SECRETOMEFebruary 2021August 2021Allow610NoNo
17269027MIC THERAPY FOR SPECIFIC IMMUNOSUPPRESSION IN TRANSPLANTATIONFebruary 2021September 2022Allow1920YesNo
17263835CONDITIONED MEDIUM AND EXTRACELLULAR MATRIX COMPOSITIONS AND USES THEREOFJanuary 2021March 2025Allow5011NoNo
17151085GENERATING CIK NKT CELLS FROM CORD BLOODJanuary 2021February 2022Allow1321NoNo
17260544GENERATING CIK NKT CELLS FROM CORD BLOODJanuary 2021November 2024Abandon4601NoNo
17133448METHOD OF ELIMINATING HEMATOPOIETIC STEM CELLS/HEMATOPOIETIC PROGENITORS (HSC/HP) IN A PATIENT USING BI-SPECIFIC ANTIBODIESDecember 2020December 2023Allow3610NoNo
17247515METHOD FOR MODULATING APPETITEDecember 2020September 2024Abandon4520NoNo
17115896INHIBITION OF CYTOKINE-INDUCED SH2 PROTEIN IN NK CELLSDecember 2020July 2021Allow710NoNo
17057646ANTI-ROR1 ANTIBODY AND USE THEREOFNovember 2020June 2024Allow4310NoNo
16953459THERAPEUTIC AND DIAGNOSTIC TARGET FOR CANCER COMPRISING DLL3 BINDING REAGENTSNovember 2020November 2023Abandon3601NoNo
17055303ANTI-MUC1 ANTIBODYNovember 2020November 2024Allow4820NoNo
17093387TREATMENT OF ASTHMA WITH ANTI-TSLP ANTIBODYNovember 2020November 2024Abandon4820NoNo
17089999HUMANIZED MONOCLONAL ADVANCED GLYCATION END-PRODUCT ANTIBODYNovember 2020November 2021Allow1200NoNo
17050299Compositions and Methods for Retrieving Tumor-related Antibodies and AntigensOctober 2020March 2025Allow5321YesNo
17050161ANTIBODY AGAINST TIM-3 AND APPLICATION THEREOFOctober 2020September 2023Allow3400NoNo
17075721THERAPEUTIC POOLED BLOOD APOPTOTIC CELL PREPARATIONS AND USES THEREOFOctober 2020September 2023Allow3510NoNo
17072703ANTI-TUMOR COMPOSITIONS AND USES THEREOFOctober 2020March 2024Abandon4111NoNo
17063204METHODS FOR DIRECTED DIFFERENTIATION OF PLURIPOTENT STEM CELLS TO IMMUNE CELLSOctober 2020June 2024Allow4420NoNo
17045130ANTI-CHEMOKIN LIKE RECEPTOR 1 ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONSOctober 2020February 2024Allow4010NoNo
17039671COMPOSITIONS AND METHODS FOR DELIVERY OF IMMUNE CELLS TO TREAT UN-RESECTABLE OR NON-RESECTED TUMOR CELLS AND TUMOR RELAPSESeptember 2020September 2023Allow3510NoNo
17028648WNT COMPOSITIONS AND METHODS FOR PURIFICATIONSeptember 2020November 2023Allow3810NoNo
17010178FUSION IMMUNOMODULATORY PROTEINS AND METHODS FOR MAKING SAMESeptember 2020May 2024Allow4520NoNo
17009558METHOD OF PRODUCING NATURAL KILLER CELLS AND COMPOSITION FOR TREATING CANCERSeptember 2020October 2023Allow3710NoNo
17007415IMMUNOGENIC WT-1 PEPTIDES AND METHODS OF USE THEREOFAugust 2020August 2023Allow3610NoNo
16976285METHODS AND COMPOSITIONS RELATING TO EPOXIDE HYDROLASE GENESAugust 2020February 2024Allow4210NoNo
16971144CD153 AND/OR CD30 IN INFECTIONAugust 2020June 2024Abandon4611NoNo
16063423DKK2 CYSTEINE RICH DOMAIN 2 CONTAINING PROTEINS AND USES THEREOFAugust 2020February 2024Abandon6010NoNo
16970473EXPANSION OF NK AND DC CELLS IN VIVO MEDIATING IMMUNE RESPONSEAugust 2020January 2024Allow4120NoNo
16986755METHODS FOR EXPANSION OR DEPLETION OF T-REGULATORY CELLSAugust 2020August 2023Allow3610NoNo
16965816COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERSJuly 2020November 2023Allow4010NoNo
16961088T CELL RECEPTORS FOR IMMUNOTHERAPYJuly 2020October 2023Allow4010YesNo
16921351EXOSOMES FOR IMMUNO-ONCOLOGY AND ANTI-INFLAMMATORY THERAPYJuly 2020February 2024Allow4420NoNo
16917156SOMATIC STEM CELLSJune 2020October 2023Abandon4010NoNo
16772967T Regulatory (Treg) Cell Transplantation in Osteogenesis Imperfecta (OI)June 2020January 2024Allow4310NoNo
16887029Compositions containing protein loaded exosome and methods for preparing and delivering the sameMay 2020August 2023Allow3810NoNo
16887971FIBROBLAST THERAPY FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHYMay 2020May 2024Allow4721NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner GAMETT, DANIEL C.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
6
Examiner Affirmed
5
(83.3%)
Examiner Reversed
1
(16.7%)
Reversal Percentile
26.3%
Lower than average

What This Means

With a 16.7% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
91
Allowed After Appeal Filing
9
(9.9%)
Not Allowed After Appeal Filing
82
(90.1%)
Filing Benefit Percentile
10.9%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 9.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner GAMETT, DANIEL C - Prosecution Strategy Guide

Executive Summary

Examiner GAMETT, DANIEL C works in Art Unit 1647 and has examined 1,090 patent applications in our dataset. With an allowance rate of 64.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 31 months.

Allowance Patterns

Examiner GAMETT, DANIEL C's allowance rate of 64.1% places them in the 17% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by GAMETT, DANIEL C receive 1.72 office actions before reaching final disposition. This places the examiner in the 50% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by GAMETT, DANIEL C is 31 months. This places the examiner in the 34% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +32.2% benefit to allowance rate for applications examined by GAMETT, DANIEL C. This interview benefit is in the 83% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 27.9% of applications are subsequently allowed. This success rate is in the 40% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 58.7% of cases where such amendments are filed. This entry rate is in the 81% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 82.9% of appeals filed. This is in the 73% percentile among all examiners. Of these withdrawals, 79.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 66.7% are granted (fully or in part). This grant rate is in the 82% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 8.2% of allowed cases (in the 94% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.4% of allowed cases (in the 61% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.